Therapy Areas: Respiratory
EMA grants orphan drug designation to Moleculin's Annamycin for AML
18 April 2024 - Clinical stage pharmaceutical company Moleculin Biotech Inc (Nasdaq:MBRX) announced on Thursday that Annamycin, its next-generation anthracycline, has received orphan drug designation ...
Circio unveils circVec proof-of-concept
17 April 2024 - Circio Holding ASA (OSE:CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, announced on Wednesday that it has established techni...
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
17 April 2024 - Germany-based pharmaceutical company Boehringer Ingelheim announced on Tuesday a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as plan...
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
16 April 2024 - Pharmaceutical company Amneal Pharmaceuticals Inc (Nasdaq: AMRX) announced on Tuesday that it has introduced PEMRYDI RTU, the inaugural ready-to-use version of pemetrexed for injection...
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
16 April 2024 - Biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) announced on Tuesday that it has completed patient enrollment in the ELEVATE IPF Phase 2b trial for LYT-100, a de...
ProAxsis secures GBP1.8m investment
15 April 2024 - Technology and life sciences VC investment group NetScientific Plc (AIM: NSCI) announced on Monday that ProAxsis Limited, a respiratory disease diagnostics company in NetScientific...